HUMA – humacyte, inc. (US:NASDAQ)

News

Humacyte (HUMA) had its "sell (e+)" rating reaffirmed by Weiss Ratings.
Humacyte (HUMA) was downgraded by Wall Street Zen from "sell" to "str
Did Humacyte, Inc. Insiders Breach their Fiduciary Duties to Shareholders? [TheStreet.com]
Did Humacyte, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Humacyte (HUMA) had its price target lowered by Barclays PLC from $3.50 to $1.50. They now have an "overweight" rating on the stock.
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com